DYAI logo

Dyadic International (DYAI) News & Sentiment

Dyadic to Attend Multiple Industry Events in March
Dyadic to Attend Multiple Industry Events in March
Dyadic to Attend Multiple Industry Events in March
DYAI
globenewswire.comMarch 6, 2025

JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced its management's participation in several prominent industry events worldwide.

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
DYAI
seekingalpha.comNovember 16, 2024

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President & CEO Joseph Hazelton - COO Patrick Lucy - Chairman Conference Call Participants John Vandermosten - Zacks Robert Hoffman - Princeton Opportunity Management Operator Operator Good evening, and welcome to Dyadic International Q3 2024 Conference Call. Currently, all participants are in a listen-only mode.

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
DYAI
globenewswire.comNovember 4, 2024

JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024.

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
DYAI
globenewswire.comJuly 30, 2024

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, August 13, 2024.

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
DYAI
globenewswire.comJune 28, 2024

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.

Dyadic to Attend Industry Events in June
Dyadic to Attend Industry Events in June
Dyadic to Attend Industry Events in June
DYAI
globenewswire.comMay 30, 2024

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, nutrition, and wellness, today announced that its management will be attending the following industry events during June 2024.

Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript
DYAI
seekingalpha.comMay 17, 2024

Dyadic International, Inc. (NASDAQ:DYAI) will be hosting its Q1 2024 Earnings Conference Call on May 14, 2024 at 5:00 PM ET. The call will feature President & CEO Mark Emalfarb, CFO Ping Rawson, and COO Joseph Hazelton. Zacks analyst John Vandermosten will also be participating. Good evening, everyone, and welcome to the conference call. Please note that all participants are currently in a listen-only mode.

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript
DYAI
Seeking AlphaMarch 28, 2024

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
DYAI
GlobeNewsWireMarch 14, 2024

JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
DYAI
Seeking AlphaNovember 8, 2023

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

  • 1(current)
  • 2
  • 1(current)
  • 2